Download Publications, 2003

Publications, 2003
Department of Oncology, Lund University Hospital, Lund
1. Adeyinka A, Baldetorp B, Mertens F, Olsson H, Johannsson O, Heim S, Pandis N:
Comparative cytogenetic and DNA flow cytometric analysis of 242 primary breast
carcinomas. Cancer Genet Cytogenet. 2003 Nov; 147(1): 62-67.
2. Baldetorp B, Bendahl PO, Ferno M, Stal O: Improved DNA flow cytometric, DNA ploidy,
and S-phase reproducibility between 15 laboratories in analysis of breast cancer using
generalized guidelines. Cytometry. 2003 Nov; 56A(1): 1
3. Borg A, Ferno M, Peterson C. Predicting the future of breast cancer Nat Med. 2003 Jan;9
(1):16-18.
4. Borgfeldt C, Bendahl PO, Ferno M, Casslen B. High preoperative plasma concentration
of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival
in patients with ovarian cancer. Gynecol Oncol. 2003 Oct; 91(1): 112-117.
5. Borgfeldt C, Bendahl PO, Gustavsson B, Langstrom E, Ferno M, Willen R, Grenman S,
Casslen B. High tumor tissue concentration of urokinase plasminogen activator receptor
is associated with good prognosis in patients with ovarian cancer.Int J Cancer. 2003 Nov
20; 107(4): 658-665.
6. Carlsson, J, Forssell Aronsson E, Hietala S-O, Stigbrand T, and Tennvall J: Tumour
therapy with radionuclides: assessment of progress and problems. Radiotherapy and
Oncology 2003; 66:107-117.
7. Chebil G, Bendahl P-O, and Fernö M: Estrogen and progesterone receptor assay in
paraffin-embedded breast cancer. Acta Oncol 2003; 42:43-37.
8. Chebil G, Bendahl P-O, Idvall I and Fernö M: Comparison of Immunohistochemical and
biochemical assay of steroid receptors in primary breast cancer. Acta Oncol 2003;
42:719-725
9. de Weert M, Oyama J, McLaughlin E, Jacobson E, Håkansson J, Bignami G, Gustafsson
U, Troy P, Poskiene V, Kriukelyte K, Ziobakiene R, Vaitkuviene A, Pålsson S, Soto
Thompson M, Stenram U, Andersson-Engels S, Svanberg S, and Svanberg K: Analysis
of spatial variability in hyperspectral imagery of the uterine cervix in vivo. SPIE
Proceedings 2003; 4959:08.
10. Dryver ET, Jernström H, Tompkins K, Buckstein R, and Imrie KR: Follow-up of patients
with Hodgkin´s disease following curative treatment: the routine CT scan is of little value.
Br J of Cancer 2003; 89: 482-486.
11. Ericson K, Halvarsson B, Nagel J, Rambech E, Planck M, Piotrowska Z, Olsson H,
Nilbert M Defective mismatch-repair in patients with multiple primary tumours including
colorectal cancer. Eur J Cancer 2003; 39(2): 240-248
12. Glimelius I, Molin D, Amini R-M, Glimelius, Enblad G: Bulky disease is the most important
prognostic factor in Hodgkin lymphoma stage IIB. Eur J Haemoatol 2003; 71: 327-333
13. Gustafson P, Åkerman M, Alvegård TA, Coindre JM, Fletcher CDM, Rydholm A, and
Willén H: Prognostic information in soft tissue sarcoma using tumour size, vascular
invasion, and microscopic tumour necrosis – the SIN-system. Eur J Cancer. 2003 Jul;
39(11): 1568-1576.
14. Gustafsson U, McLaughlin E, Jacobson E, Håkansson J, Troy P, de Weert M, Pålsson S,
Soto Thompson M, Svanberg S, Vaitkuviene A, and Svanberg K: Fluorescence and
reflectance monitoring of human cervical tissue in vivo – A case study. SPIE
Proceedings 2003; 4959:12.
15. Hardell L, Eriksson M, Axelson O, Flesch-Janys D: Epidemiological studies on cancer
and exposure to dioxins and related compounds. Chapter 18. In: Schector A, Gasiewicz
TA. Dioxins and Health, 2nd ed. John Wiley & Sons, Inc. 2003; 729-764
16. Hardell L, van Bavel B, Lindstrom G, Carlberg M, Dreifaldt AC, Wijkstrom H,
Starkhammar H, Eriksson M, Hallquist A, Kolmert T. Increased concentrations of
polychlorinated biphenyls, hexachlorobenzene, and chlordanes in mothers of men with
testicular cancer. Environ Health Perspect. 2003 Jun; 111(7): 930-934.
17. Hertervig E, Nilsson Å, Nilbert M, Duan R-D. Reduction in alkaline sphingomyelinase in colorectal
tumorigenesis is not realted to the APC gene mutation. Int J Colorectal Dis 2003; 18: 309-313
18. Idvall I, Anderson H, Ringberg A, and Fernö M: Are cellular polarisation and mitotic
frequency prognostic factors for local recurrence in patients with ductal carcinoma in situ
of the breast? Eur J Cancer 2003; 39:1704-1710.
19. Jernström H, Bendahl P-O, Lidfeldt J, Nerbrand C, Agardh C-D, and Samsioe G A
prospective study of different types of hormone replacement therapy use and the risk of
subsequent breast cancer: the women´s health in the Lund area (WHILA) study
(Sweden) Cancer Causes and Control 2003, 14: 673-680
20. Jernström H, Klug TL, Sepkovic DW, Bradlow HL, and Narod SA: Predictors of the
plasma ratio of 2-hydroxyestrone to 16-hydroxyestrone among pre-menopausal,
nulliparous women from four ethnic groups. Carcinogenesis 2003; 24 No 5: 991-1005.
21. Jirström K, Ringberg A, Fernö M, Anagnostika L, Landberg G. Tissue microarray
analyses of G I/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that
low cyclin D I is associated with local recurrence. British journal of Cancer 2003; 89:
1920-1926
22. Johannsson O, Staff S, Vallon-Christersson J, Kytöla S, Gudjonsson T, Rennstam K,
Hedenfalk I, Adeyinka A, Kjellén E, Wennerberg J, Baldetorp B, Petersen O, Olsson H,
Oredsson S, Isola J, and Borg Å: Characterization of a novel breast carcinoma xenograft
and cell line derived from a BRCA1 germ-line mutation carrier. Lab Invest. 2003 Mar;
83(3): 387-96.
23. Kinhult S, Albertsson M, Eskilsson J, and Cwikiel M: Effects of propucol on endothelial
damage by 5-fluorouracil. Acta Oncol 2003; 42(4): 304-308.
24. Kinhult S, Eskilsson J, Albertsson M, and Cwikiel M: Endothelial damage after treatment
with low-molecular weight heparins – a morphological study. Scand Cardiovasc J 2003;
37: 30-33.
25. Kühling H, Alm P, Olsson H, Fernö M, Baldetorp B, Parwaresch R. Expression of cyclins
E, A, and B, and prognosis in lymph node-negative breast cancer. J Patology, 2003;199:
424-431
26. Li C, Samsioe G, Borgfeldt C, Bendahl P-O, Wilawan K, Åberg A. Low-dose hormone
therapy and carbohydrate metabolism. Fertility and Sterility 2003; 79(3): 500-555
27. Lindell G, Holmin T, Ewers SB, Tranberg KG, Stenram U, Ihse I. Extended operation with
or without intraoperative (IORT) and external (EBRT) radiotherapy for gallbladder
Hepatogastroenterology. 2003; 50(50): 310-314.
28. Linderoth J, Jerkeman M, Cavallin-Ståhl E, Kvaløy S, and Torlakovic E:
Immunohistochemical expression of CD23 and CD40 may identify prognostically
2017-05-14/sa
2
favourable subgroups of diffuse large B-cell lymphoma: A Nordic Lymphoma Group
Study. Clin Cancer Res 2003; 9:722-728.
29. Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, Kates R,
Spyratos F, Ferno M, Eppenberger-Castori S, Fred Sweep CG, Ulm K, Peyrat JP, Martin
PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendah PO, Quillien V, Daver A,
Ricolleau G, Meijer-van Gelder M, Manders P, Edward Fiets W, Blankenstein M, Broet P,
Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex L, Klijn
J, O'Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens J. Pooled analysis of
prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost. 2003
Sep; 90(3): 538-548.
30. Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, Rosenblad E,
Tjønnfjord G, Wiklund T, and Österborg A: Phase II study of alemtuzumab (anti-CD52
monoclonal antibody, Campath-1H) in patients with advanced mycosis fungoides/Sézary
syndrome. Blood. 2003 Jun 1; 101(11): 4267-4272.
31. Lydrup M-L, Fernö M: Correlation between estrogen receptor alpha expression, collagen
content and stiffness in human uterine arteries. Acta Obstet Gynecol Scand. 2003 Jul;
82(7): 610-615.
32. Malmström P, Holmberg L, Anderson H, Mattson J, Jönsson P-E, Tennvall-Nittby L,
Svensson J-H, Ingvar C, Möller T, Holmberg E, and Wallgren A: Breast conservation
surgery, with and without radiotherapy, in women with lymph node-negative breast
cancer: a randomised clinical trial in a population with access to public mammography
screening.
Eur J Cancer. 2003 Aug; 39(12): 1690-1697.
33. Molin D, Enblad G, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, and Glimelius
B: Early and intermediate stage Hodgkin lymphoma – report from the Swedish national
care programme. Eur J Haematol. 2003 Mar; 70(3): 172-180
34. Norum Pedersen L, Kaerlev L, Stubbe Teglbjaerg P, Olsen J, Eriksson M, Guenel P,
Ahrens W, Ballard T, Autrup H.Glutathione S-transferase genotype and p53 mutations in
adenocarcinoma of the small intestine. Scand J Gastroenterol. 2003 Aug; 38(8): 845-849.
35. Olsson H. What can we learn from the Million Women Study. Maturitas. 2003 Oct 20;
46(2): 87-9
36. Olsson H, Baldetorp B, Fernö M, and Perfekt R: Relation between the rate of tumour cell
proliferation and latency time in radiation associated breast cancer.
BMC Cancer. 2003 Apr 9; 3(1): 11.
37. Olsson H, Ingvar C, and Bladström A: Hormone replacement therapy containing
progestins and given continuously increases breast carcinoma risk in Sweden. Cancer.
2003; 97: 1387-1392.
38. Olsson H, Bladström A, Ingvar C: Are smoking-associated cancers prevented or
postponed in women using hormone replacement therapy? Obstet Gynecol. 2003
Sep;102(3):565-70
39. Olsson H, Ingvar C, Bladström A. Author reply Cancer 2003; 98(7):1553-1554
40. Ösby E, Hagberg H, Kvaløy S, Teerenhovi L, Anderson H, Cavallin-Ståhl E, Holte H,
Myhre J, Pertovaara H, and Björkholm M: CHOP is superior to CNOP in elderly patients
with aggressive lymphoma while outcome is unaffected by filgrastim treatment: Results of
a Nordic Lymphoma Group randomized trial. Blood. 2003 May 15; 101(10): 3840-3848.
2017-05-14/sa
3
41. Planck M, Ericson K, Piotrowska Z, Halvarsson B, Rambech E, Nilbert M. Microsatellite
instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.
Cancer 2003; 97(6): 1551-1557
42. Pålsson S, Gustafsson L, Bendsoe, N, and Soto M: Kinetics of superficial blood
perfusion and temperature in connection with photodynamic therapy of basal cell
carcinomas using esterified and non-esterified 5-aminolevulinic acid. Br J Dermatology.
2003 Jun; 148(6): 1179-1188.
43. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl P-O, Borg Å, Karhu R, Tanner M,
Tirkkonen M, Isola J.Patterns of chromosomal imbalance defines subgroups of breast
cancer with distinct clinical features and prognostic. A study of 305 tumours by
comparative genomic hybridization. Cancer Research 2003;63:8861-8868.
44. Relander T: Retroviral gene transfer to repopulating hematopoietic cells. Lund
University 2003. 28-02-2003 PhD. Dr in Medical Science.
45. Richter J, Relander T, Fasth A, and Karlsson S: Bakslag för genterapi: Två fall av
leukemi I fransk studie. Läkartidningen 2003; No 7, 498-500.
46. Ridderheim M, Bjurberg M, and Gustavsson A: Scalp hypothermia to prevent
chemotherapy-induced alopecia is effective and safe: A pilot study of a new digitalized
scalp cooling system used in 74 patients. Supportive Care in Cancer 2003; 11: 371377.
47. Rudolph P, Kühling H, Alm P, Fernö M, Baldetorp B, Olsson H, Parwaresch R.
Differential prognostic impact of the cyclins E and B in premenopausal and
postmenopausal women with lymph nonde-negative breast cancer. Int J Cancer
2003;106:674-680.
48. Schildt EB, Nylander K, Eriksson M, Hardell L, Magnusson A, and Roos G: Expression of
p53, PCNA, Ki-67 and bcl-2 in relation to risk factors in oral cancer – a molecular
epidemiological study. Int J of Oncology 2003; 22:861-868.
49. Wang Zh, Garkavij M, Ohlsson Th, Strand S-E, Sjögren H-O, and Tennvall J:
Biotinylation. Biotinylation, pharmacokinetics, and extracorporeal adsorption of
humanized MAb 111In-MN14 using an avidin-affinity column in rats. Cancer Biotherapy
& Radiopharmaceuticals. 2003 Jun; 18(3): 365-375.
2017-05-14/sa
4